| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
5,000 |
8,704 |
24,601 |
181,935 |
| Total Sell Value |
$548,250 |
$986,699 |
$3,178,219 |
$26,303,629 |
| Total People Sold |
1 |
2 |
12 |
19 |
| Total Sell Transactions |
1 |
3 |
19 |
67 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Enright Patrick G |
Director |
– • – |
2017-08-11 |
4 |
S |
$142.36 |
$94,248 |
D/D |
(662) |
2,068 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
7,441 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
13,472 |
|
- |
|
| Gray Peter |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
8,119 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
6,599 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
11,756 |
|
- |
|
| Schnee Elmar |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
6,540 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
7,481 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
6,318 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
1,049,373 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2017-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,365 |
2,730 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2017-08-07 |
4 |
D |
$155.56 |
$152,138 |
D/D |
(978) |
51,985 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2017-07-20 |
4 |
AS |
$160.00 |
$732,800 |
D/D |
(4,580) |
32,322 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-07-17 |
4 |
AS |
$154.97 |
$30,994 |
D/D |
(200) |
22,196 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2017-06-23 |
4 |
AS |
$160.00 |
$67,200 |
D/D |
(420) |
36,902 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-06-15 |
4 |
AS |
$150.65 |
$30,130 |
D/D |
(200) |
22,223 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2017-06-01 |
4 |
S |
$150.00 |
$750,000 |
D/D |
(5,000) |
10,391 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-05-15 |
4 |
AS |
$152.98 |
$30,596 |
D/D |
(200) |
22,423 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2017-05-12 |
4 |
D |
$153.79 |
$125,339 |
D/D |
(815) |
39,533 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
22,623 |
|
- |
|
| Smith Karen L. |
EVP, R&D and CMO |
• – – |
2017-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
21,527 |
|
- |
|
| Smith Karen L. |
EVP, R&D and CMO |
• – – |
2017-05-11 |
4 |
D |
$155.18 |
$99,470 |
D/D |
(641) |
20,527 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2017-05-11 |
4 |
S |
$153.17 |
$4,604,146 |
D/D |
(30,000) |
278,491 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2017-05-09 |
4 |
AS |
$160.00 |
$400,000 |
D/D |
(2,500) |
37,149 |
|
- |
|
| Miller Michael Patrick |
EVP, US Commercial |
• – – |
2017-05-05 |
4 |
D |
$159.06 |
$149,357 |
D/D |
(939) |
21,623 |
|
- |
|
1250 Records found
|
|
Page 22 of 50 |
|
|
0.37 (0.34%) 
